Many efforts to persuade others politically employ interpersonal conversations. A recurring question is whether the participants in such conversations are more readily persuaded by others who share their demographic characteristics. Echoing concerns that individuals have difficulties communicating across differences, research finds that individuals perceive demographically similar people as more trustworthy, suggesting shared demographics could facilitate persuasion. In a survey of practitioners and scholars, we find many share these expectations. However, dual-process theories suggest that messenger attributes are typically peripheral cues that should not influence persuasion when individuals are effortfully thinking, such as during interpersonal conversations. Supporting this view, we analyze data from eight experiments on interpersonal conversations across four topics (total N = 6, 139) and find that shared demographics (age, gender, or race) do not meaningfully increase their effects. These results are encouraging for the scalability of conversation interventions, and suggest voters can persuade each other across differences.

Asymptomatic coronavirus disease 2019 (COVID-19) has been reported as a significant driver of COVID-19 outbreaks. Our hospital ward outbreak analysis suggests that comprehensive symptoms and signs assessment, in combination with adequate follow-up, allows a more precise determination of COVID-19 symptoms. Asymptomatic infection was quite uncommon among adults in this setting.

Introduction. Individuals with psychotic-spectrum disorders may smoke due to the ameliorating effect of nicotine on the cognitive deficits that accompany these illnesses. Metacognitive remediation therapy (MCR) has been shown to produce improvements in cognitive functioning among individuals with psychotic-spectrum disorders and provides a foundation for a novel smoking cessation intervention for this population. Aims. To complete an open investigation of pharmacotherapy and a modified version of MCR [MCR to Quit (MCR-Q)] in promoting smoking cessation among individuals with psychotic-spectrum disorders. Methods. Forty-nine individuals with a psychotic-spectrum disorder and who currently smoke cigarettes participated in MCR-Q while also receiving evidence-based smoking cessation pharmacotherapy. Tobacco use was assessed as follows: (i) prior to MCR-Q, (ii) immediately after completing MCR-Q, and (iii) six weeks after completion of MCR-Q. Results/Findings. During participation in MCR-Q, nearly 80% of participants made a 24-hour quit attempt. Following the completion of MCR-Q, participants experienced reductions in level of nicotine dependency and exhaled carbon monoxide, with reductions in nicotine dependency sustained six weeks after completion of MCR-Q. Over the course of their participation in MCR-Q, participants reported strong therapeutic alliance with their MCR-Q therapist and high levels of intrinsic motivation with regard to completing MCR-Q exercises. Conclusions. The results from the current study suggest cautious optimism with regard to the use of MCR-Q in combination with medication for individuals with psychotic-spectrum disorders who want to quit smoking.